Digoxin - Therapeutic Drug Monitoring and Toxicity

Key Points

• Draw digoxin levels after the distribution phase; early post-dose concentrations are misleading.
• Interpret the level together with symptoms, kidney function, electrolytes, and ECG.
• CKD and interacting P-glycoprotein drugs increase toxicity risk.
• Hypokalemia and hypomagnesemia increase myocardial sensitivity to digoxin.
• Chronic toxicity can present with nonspecific GI or neurologic symptoms.
• Acute severe toxicity may cause hyperkalemia and malignant arrhythmias.
• Digoxin immune Fab is the antidote for severe or life-threatening toxicity.
• Routine digoxin levels become difficult to interpret after Fab administration.

Algorithm

1. Stop digoxin and obtain ECG, renal function, potassium, magnesium, calcium, and appropriately timed level.
2. Assess hemodynamic stability and characterize the rhythm.
3. Correct important electrolyte abnormalities and provide supportive arrhythmia management.
4. Consult toxicology/poison control for significant toxicity.
5. Administer digoxin immune Fab when severe indications are present.
6. Monitor ECG and potassium closely after Fab because potassium can fall rapidly.
7. Identify renal decline or interacting medication that precipitated toxicity.
8. Reassess the ongoing indication and dose before any restart.

Clinical Synopsis & Reasoning

Digoxin inhibits the sodium-potassium ATPase, increasing intracellular calcium in cardiac myocytes and enhancing vagal tone at the AV node. It is used selectively in heart failure and atrial fibrillation, but modern therapy has reduced its routine role. The narrow therapeutic window makes patient selection and dose monitoring important, especially in older adults and CKD.

Serum digoxin should be measured after the distribution phase, generally at least several hours after an oral or IV dose, because an early post-dose level can be falsely high and does not reflect equilibrated tissue exposure. In chronic heart-failure therapy, lower serum concentrations are generally favored over historical higher targets. The number must be interpreted with symptoms rather than used as an isolated toxicity cutoff.

Kidney function is a major determinant of elimination. Hypokalemia and hypomagnesemia increase myocardial sensitivity to digoxin, while hypercalcemia can worsen arrhythmogenicity. Diuretics can therefore create toxicity risk even when the digoxin dose has not changed. Interacting drugs such as amiodarone, verapamil, quinidine, and some macrolides can raise exposure through P-glycoprotein or clearance effects.

Chronic toxicity often presents nonspecifically with anorexia, nausea, weakness, confusion, or bradycardia before a dramatic arrhythmia appears. Acute large ingestion can produce hyperkalemia because sodium-potassium ATPase blockade shifts potassium extracellularly. A wide variety of rhythm disturbances is possible; a new arrhythmia in a digoxin-treated patient with renal decline deserves urgent evaluation.

Treatment Strategy & Disposition

For suspected toxicity, stop digoxin and obtain ECG, potassium, magnesium, calcium, renal function, and a properly timed serum digoxin level. Treat unstable bradycardia or tachyarrhythmia according to toxicology/ACLS principles while correcting electrolytes. Avoid reflexive calcium avoidance in life-threatening hyperkalemia solely because digoxin toxicity is suspected; contemporary toxicology practice prioritizes membrane stabilization when indicated, although digoxin immune Fab is the definitive antidote for severe toxicity.

Give digoxin immune Fab for life-threatening ventricular arrhythmias, hemodynamically significant bradyarrhythmias/AV block unresponsive to routine measures, cardiac arrest, severe hyperkalemia from acute toxicity, or other severe poisoning according to poison-center/toxicology guidance. Dose can be based on known ingestion, steady-state concentration, or empiric vial strategies. After Fab, routine digoxin assays measure both bound and unbound drug and are difficult to interpret.

In stable chronic toxicity, supportive care, dose reduction or discontinuation, correction of renal/electrolyte issues, and review of interacting drugs may be sufficient. Hemodialysis does not remove digoxin effectively because of its large volume of distribution.

After recovery, reassess whether digoxin remains necessary and restart at a lower renal-adjusted dose only when benefit is clear. If it was being used for AF rate control, optimize other rate-control therapy as tolerated; if used for heart failure, ensure contemporary guideline-directed therapy is addressed.

Epidemiology / Risk Factors

• Digoxin use is concentrated in older patients with atrial fibrillation or selected heart-failure indications.
• Renal impairment and polypharmacy make toxicity more common in older adults.
• Most toxicity is chronic accumulation rather than a single massive ingestion.
• Medication reconciliation after hospitalization is a common opportunity to prevent recurrence.

Investigations

Toxicity Clues

Pharmacology

Prognosis / Complications

• Mild chronic toxicity generally resolves with discontinuation and correction of precipitating factors.
• Severe arrhythmia or hyperkalemia can be fatal without timely Fab.
• Renal failure can prolong toxicity substantially if Fab is not indicated or not used.
• Recurrence is preventable by renal-adjusted dosing and interaction monitoring.

Patient Education / Counseling

• Take digoxin at the same time daily and do not double a missed dose.
• Report persistent nausea, loss of appetite, unusual confusion, severe weakness, fainting, or palpitations.
• Tell clinicians and pharmacists you take digoxin before starting antibiotics, amiodarone, verapamil, or other interacting medicines.
• Keep kidney and electrolyte laboratory appointments.
• After a toxicity episode, confirm the new dose or discontinuation plan before resuming tablets at home.

Notes

Digoxin is a classic example of why therapeutic drug monitoring is not just a number. Timing, symptoms, renal function, potassium, and drug interactions can make the same measured concentration clinically benign in one patient and dangerous in another.

After digoxin immune Fab, total serum digoxin may rise dramatically because assays detect Fab-bound drug. Management should follow the patient's rhythm, perfusion, potassium, and clinical response rather than chasing that laboratory value.

References

1. AHA arrhythmia and digitalis toxicity resources — Link
2. FDA labeling for digoxin immune Fab — Link